Endonovo Therapeutics
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
6320 Canoga Ave Fl 15, Woodland Hills, C...Phone Number
(800) 489-4774Website
www.endonovo.comRevenue
<$5 MillionStock Symbol
ENDVIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial stage developer of non-invasive medical devices that deliver proprietary Electroceutical Therapy aimed at treating inflammatory conditions, cardiovascular diseases, and central nervous system disorders. Their FDA-Cleared therapy is designed for the palliative treatment of pain and post-surgical edema, and it has received CE Mark for promoting wound healing. The company's clinical pipeline focuses on conditions such as ischemic heart disease, concussions, traumatic brain injury, and multiple sclerosis. Endonovo's vision is to create safe, wearable devices that utilize bioelectricity to enhance healing processes.Explore more
Endonovo Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Endonovo Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Endonovo Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Endonovo Therapeutics
Website visits: Recent activity has been detected on your website
Check out if Endonovo Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Endonovo Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Endonovo Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Endonovo Therapeutics has new funding data
Click to see if Endonovo Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Endonovo Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined Endonovo Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Endonovo Therapeutics
Compare insights from companies similar to Endonovo Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Endonovo Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Endonovo Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Endonovo Therapeutics.
Endonovo Therapeutics Tech Stack
A closer look at the technologies used by Endonovo Therapeutics
Most Recent Scoops
New Hire
Executive Move
Mergers & Acquisitions (M&A)
Funding
Endonovo Therapeutics recently secured $5 million in post IPO debt funding.
Funding
Funding
Endonovo Therapeutics recently secured $10 million in post IPO equity funding.
Funding
Funding
Funding
Endonovo Therapeutics News & Media
Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
Los Angeles, CA, March 28, 2024 (GLOBE NEWSWIRE) -- Endonovo (OTC PINK: ENDV) and its subsidiary, SofPulse, Inc., today announced they have finalized and completed the Asset Purchase Agreement (APA), originally signed in December 2023, for the acquisition of Endonovo's assets and Intellectual Property (IP) for a minimum of $50 million.Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
US Army Medical Research and Development Command Vendor DayEndonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives marketed under the SofPulse® brand name, announced the signing of a definitive agreement for the sale of the SofPulse® business and medical Intellectual Property (IP) to SofPulse, Inc.. ENDV is expected to receive the greater of $50 million or a price to be determined by a qualifiedEndonovo's SofPulse® Secures Taiwan FDA Approval
Los Angeles, CA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) US-based medical device company, today announced the full regulatory approval of its flagship product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Endonovo Therapeutics
Sign Up For FreeTo access detailed company insights
Endonovo Therapeutics is a commercial stage developer of non-invasive medical devices that deliver proprietary Electroceutical Therapy aimed at treating inflammatory conditions, cardiovascular diseases, and central nervous system disorders. Their FDA-Cleared therapy is designed for the palliative treatment of pain and post-surgical edema, and it ha... Read More
